Overview
Jianjun Han practices practicing medicine in Handan, China.
Han is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, Hemolytic Transfusion Reaction, and Esophageal Cancer.
They are actively involved in clinical research, co-authoring 25 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jianjun Han
Is Jianjun Han a top-rated expert for Triple-Negative Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Jianjun Han is classified as an Advanced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jianjun Han participate in research or clinical trials?
Yes. Jianjun Han has published 25 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Jianjun Han's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Triple-Negative Breast Cancer
- Experienced
- Breast CancerHan isExperienced. Learn about Breast Cancer.
- Esophageal CancerHan isExperienced. Learn about Esophageal Cancer.
- Hemolytic Transfusion Reaction